NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
Rhea-AI Summary
NewcelX (Nasdaq: NCEL) announced a private placement priced at $2.75 per share, a 30% premium to the March 31, 2026 close, selling 490,907 common shares and warrants to purchase 687,270 shares at a $3.025 exercise price.
Proceeds, together with a previously announced $25 million equity line, are intended to advance NCEL-101 for Type 1 Diabetes, other pipeline programs, working capital and general corporate purposes; closing is expected on or about April 15, 2026 subject to customary conditions.
Positive
- Pricing at $2.75 per share, a 30% premium to March 31, 2026 close
- Private placement includes warrants to buy 687,270 common shares at $3.025
- Net proceeds plus a $25 million equity line to fund NCEL-101 development
Negative
- Issuance of 490,907 shares and warrants may dilute existing shareholders
- Closing subject to customary conditions, expected on or about April 15, 2026
News Market Reaction – NCEL
On the day this news was published, NCEL gained 10.85%, reflecting a significant positive market reaction. Argus tracked a peak move of +2.7% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $11.24M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No biotech peers flagged in the momentum scanner and no same-day peer headlines provided, indicating the 12.77% move was stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 09 | NCEL-101 collaboration | Positive | -1.1% | Partnered NCEL-101 with Eledon’s tegoprubart to enhance T1D islet replacement. |
| Feb 12 | Publication & CVR update | Positive | +1.1% | Peer-reviewed Mazindol IR/SR data supporting Mazindol ER and CVR monetization talks. |
| Jan 29 | Corporate presentation | Positive | -3.4% | Updated deck emphasizing Type 1 Diabetes cell therapy focus and conference outreach. |
| Jan 12 | Biomaterials study results | Positive | +13.7% | Positive study on ECM-integrated scaffolds for stem cell–derived islet delivery in T1D. |
| Jan 05 | SAB appointment | Positive | +6.7% | Added diabetes-focused big pharma leader to SAB to guide IsletRx development. |
Stock has often reacted positively to R&D and management updates, with occasional divergences where positive strategic or partnership news coincided with modest pullbacks.
Over the last few months, NewcelX has focused on Type 1 Diabetes cell therapy and its NCEL-101 program. On Jan 5, a diabetes expert joined its Scientific Advisory Board, followed by positive biomaterials study results on Jan 12 and an updated strategic presentation on Jan 29. A peer-reviewed Mazindol publication and CVR update came on Feb 12, and a collaboration with Eledon around NCEL-101 was announced on Mar 9. Today’s premium-priced financing supports this same T1D-focused development path.
Market Pulse Summary
The stock surged +10.8% in the session following this news. A strong positive reaction aligns with a premium-priced financing that brought in $1.35 million at $2.75 per share, a 30% premium to the last close. The move also fits past patterns where positive scientific and strategic updates, such as the Jan 12 biomaterials data and Jan 5 SAB addition, coincided with gains. Investors watching sustainability may focus on execution of NCEL-101 milestones and deployment of the $25 million equity line.
Key Terms
securities purchase agreements financial
private placement financial
warrants financial
exercise price financial
equity line financial
Regulation D regulatory
registration statement regulatory
AI-generated analysis. Not financial advice.
Financing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program
ZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for Type 1 Diabetes, today announced that it has entered into securities purchase agreements for a private placement at a purchase price of
Pursuant to the terms of the securities purchase agreements, the Company is selling an aggregate of 490,907 common shares (and common share equivalents) and one series of warrants to purchase an aggregate of 687,270 common shares at an exercise price of
The offering includes participation from existing shareholders and is expected to close on or about April 15, 2026, subject to the satisfaction of customary closing conditions.
The Company intends to use the net proceeds from the offering, together with its previously announced
“We are very pleased to secure funding at a
The securities described above are being issued in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and Regulation D promulgated thereunder and have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About NewcelX
NewcelX is an innovative biopharmaceutical company focused on developing transformative stem-cell-derived therapies for Type 1 Diabetes. Built on a validated human pluripotent stem cell (hPSC) platform, the Company’s lead program, NCEL-101, is designed to restore functional insulin production through scalable, off-the-shelf cell replacement. NewcelX is advancing a comprehensive therapeutic approach for Type 1 Diabetes integrating cell therapy, immune protection, and translational science to address critical unmet medical needs.
Social Media: LinkedIn, Facebook, X, Instagram
Website: www.newcelx.com
Forward-Looking Statements
This press release contains expressed or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. For example, NewcelX is using forward-looking statements when it discusses the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering and the intended use of proceeds therefrom. These forward-looking statements and their implications are based on the current expectations of the management of NewcelX and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; potential delays or obstacles in launching or completing clinical trials; products that may not be approved by regulatory agencies; technologies that may not be validated or accepted by the scientific community; the inability to retain or attract key employees; unforeseen scientific difficulties with products in development; higher-than-expected product costs; results in the laboratory that do not translate to clinical success; insufficient patent protection; possible adverse safety outcomes; legislative changes; delays in developing or introducing new technologies, products, or applications; and competitive pressures that could reduce market share or pricing. Except as otherwise required by law, NewcelX does not undertake any obligation to publicly release revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in its Annual Report on Form 20-F for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (“SEC”) and available at www.sec.gov, as well as in subsequent filings made by NewcelX, including under the heading “Risk Factors” in its proxy statement/prospectus filed with the SEC on November 6, 2025.
Investor & Media Contacts
Sarah Bazak, Investors relations
InvestorRelations@newcelx.com
FAQ
What did NewcelX (NCEL) announce about the April 1, 2026 private placement?
What is NewcelX (NCEL) using the April 2026 financing proceeds for?
When is NewcelX (NCEL) expected to close the April 2026 private placement?
At what exercise price are the NewcelX (NCEL) warrants issued in April 2026?
